louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT00681590: Safety of Vitamin D Supplementation in Older Persons
Official title: Safety of Vitamin D Supplementation in the Elderly
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: Vitamin D Deficiency
Keywords: vitamin D
deficiency
elderly
Lead sponsor: University of Miami
Sponsor class: OTHER
Collaborators: name: Merck Sharp & Dohme LLC
First posted: 2008-05-21
Enrollment: 105
Sex: ALL
Minimum age (years): 65
Maximum age (years): 95
Standard ages: OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: This study will evaluate the safety over 6 months of two different doses of vitamin D (cholecalciferol) in men and women age 65 and older. It will also evaluate if supplementation with vitamin D improves physical performance.

Detailed description: 120 ambulatory men and women ages 65 to 95 will be enrolled in this study. Each subject will participate in the clinical trial for 6 months.

Parathyroid hormone, vitamin D, and serum and urinary calcium will be measured periodically. Physical performance will be tested at baseline and throughout the study.

Eligibility criteria: Inclusion Criteria:

* ambulatory

Exclusion Criteria:

* hypercalcemia
* hypercalciuria \> 4 mg/kg body weight/day
* primary, secondary, or tertiary hyperparathyroidism
* renal insufficiency (serum creatinine \> 2 mg/dL )
* history of nephrolithiasis
* treatment with vitamin D (ergocalciferol, cholecalciferol, calcitriol)
* treatment with anticonvulsants
* Paget's disease
* severe cardiac, pulmonary, hepatic, renal, or neurological disease
* life expectancy \< 1 year
* participation in another trial

Primary outcomes:
measure: Number of Participants Who Develop Hypercalcemia
timeFrame: 6 months
Secondary outcomes:
measure: Change From Baseline in Serum 25-hydroxyvitamin D Levels
timeFrame: baseline and 6 months
Other outcomes:
Locations:
city: Miami
country: United States
facility: University of Miami
state: Florida
Study officials:
affiliation: University of Miami
name: Silvina Levis, MD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Lagari V, Gomez-Marin O, Levis S. The role of vitamin D in improving physical performance in the elderly. J Bone Miner Res. 2013 Oct;28(10):2194-201. doi: 10.1002/jbmr.1949.
citation: Lagari VS, Gomez-Marin O, Levis S. Differences in vitamin D3 dosing regimens in a geriatric community-dwelling population. Endocr Pract. 2012 Nov-Dec;18(6):847-54. doi: 10.4158/EP12081.OR.
Clinical trial NCT00002390: A Study of the Safety and Effectiveness of Different Doses of 1592U89 in HIV-Infected Patients
Official title: A Phase II Randomized, Blinded, Dose-Ranging Multicenter Study to Evaluate the Safety and Efficacy of Different Regimens of 1592U89 Monotherapy Upon Selected Immunological and Virological Markers of HIV-1 Infection in Antiretroviral Therapy-Naive Patients
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: HIV Infections
Lead sponsor: NIH AIDS Clinical Trials Information Service
Sponsor class: INDUSTRY
First posted: 2001-08-31
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to see if giving 1592U89 to HIV-infected patients is safe and effective in lowering viral load (level of HIV in the blood) and raising the level of CD4 cells (cells of the body that help fight infection).

Detailed description: Patients are randomized to receive one of three doses of 1592U89. During this randomized dosing phase, if a patient meets one of the following criteria, he/she is offered open-label 1592U89 (300 mg) plus zidovudine (ZDV) plus lamivudine (3TC) (or other licensed antiretrovirals according to standard practice). Criteria are based on falling CD4 counts (return to baseline on two occasions at least 1 month apart), disease progression (defined as occurrence of a new AIDS-defining event according to CDC classification excluding CD4 counts less than 200 cells/mm3), or lack of virus suppression (defined as less than 0.7log10 reduction in viral load at Week 4 with a repeat value 1 week later, more than 5000 copies/ml HIV RNA at Weeks 12, 16, 20, or 24, or 5000 copies/ml or more anytime after Week 24).


Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Paris Cedex 13
country: France
facility: Group Hospier Pitie-Salpetriere / Maladies Infec et Trop
city: Paris Cedex 18
country: France
facility: Groupe Hospitalier Bichat-Claude Bernard
city: Toulouse Cedex
country: France
facility: Hopital de Purpan / CHU de Rangueil / Medecine Interue
city: Toulouse Cedex
country: France
facility: Hopital de Purpan / Service du Professeur Auvergnat
city: Erlangen
country: Germany
facility: Universitat Erlangen
city: Frankfurt
country: Germany
facility: Universitatsklinikurn Frankfurt
Study officials:
References:
citation: Staszewski S, Katlama C, Harrer T, Massip P, Yeni P, Cutrell A, Tortell SM, Harrigan RP, Steel H, Lanier RE, Pearce G. A dose-ranging study to evaluate the safety and efficacy of abacavir alone or in combination with zidovudine and lamivudine in antiretroviral treatment-naive subjects. AIDS. 1998 Nov 12;12(16):F197-202. doi: 10.1097/00002030-199816000-00001.
Clinical trial NCT02762890: Comparison of Deep Neuromuscular Block and Moderate Neuromuscular Block on Quality of Recovery in Patients Undergoing Robotic Gastrectomy
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: General Anesthesia
Lead sponsor: Yonsei University
Sponsor class: OTHER
First posted: 2016-05-05
Enrollment: 56
Sex: ALL
Minimum age (years): 19
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: The purpose of this study is to investigate and compare the postoperative quality of recovery between the deep neuromuscular blockade and moderate neuromuscular blockade during robotic gastrectomy.


Eligibility criteria: Inclusion Criteria:

* adult patients aged 19-80 years who are scheduled for robotic gastrectomy

Exclusion Criteria:

* Neuromuscular disease
* History of malignant hyperthermia
* Significant renal or hepatic dysfunction
* Allergy to sugammadex or rocuronium

Primary outcomes:
measure: Postoperative quality of recovery
timeFrame: within 48 hours after the end of surgery.
Secondary outcomes:
measure: Surgical condition
timeFrame: within 48 hours after the end of surgery
measure: shoulder pain
timeFrame: within 48 hours after the end of surgery
measure: abdominal pain
timeFrame: within 48 hours after the end of surgery
measure: nausea and vomiting
timeFrame: within 48 hours after the end of surgery
Other outcomes:
Locations:
city: Seoul
country: Korea, Republic of
facility: Department of Anesthesiology and Pain Medicine Anesthesia and Pain Research Institute Yonsei University
Study officials:
References:
Clinical trial NCT03160690: Changes in Choroidal Thickness After Non Penetrating Deep Sclerectomy
Official title: Changes in Choroidal Thickness After Non Penetrating Deep Sclerectomy
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Choroidal Thickness
Open Angle Glaucoma
Non Penetrating Deep Sclerectomy
Keywords: Choroidal thickness
Open Angle Glaucoma
Non penetrating deep sclerectomy
Lead sponsor: Germans Trias i Pujol Hospital
Sponsor class: OTHER
Collaborators: name: Pau Romera Romero
name: Jorge Loscos Arenas
name: Nevena Romanic Bubalo
name: Jordi Castellví Manent
First posted: 2017-05-19
Enrollment: 20
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients with progressive open angle glaucoma although topical treatment with indication for non penetrating deep sclerectomy

Brief summary: Prospective and observational study to determine if choroidal thickness increases after non penetrating deep sclerectomy in patients with open angle glaucoma


Eligibility criteria: Inclusion Criteria:

* Progressive Primary Open Angle Glaucoma

Exclusion Criteria:

* Age under 18yrs
* Myopia or Hyperopia higher than -6D or +6D
* Secondary glaucoma
* Ocular surgery other than cataract
* Other ocular pathology

Primary outcomes:
measure: Change in Choroidal thickness
timeFrame: before and 1 week, 1 month, 3 months and 6 months after non penetrating deep sclerectomy
measure: Change in Intraocular pressure
timeFrame: before and 1 week, 1 month, 3 months and 6 months after non penetrating deep sclerectomy
Secondary outcomes:
Other outcomes:
Locations:
city: Badalona
country: Spain
facility: Germans Trias i Pujol Hospital
state: Barcelona
Study officials:
affiliation: Germans Trias i Pujol Hospital
name: Sandra Gómez Sánchez, MD
role: PRINCIPAL_INVESTIGATOR
affiliation: Germans Trias i Pujol Hospital
name: Pau Romera Romero, MD
role: PRINCIPAL_INVESTIGATOR
affiliation: Germans Trias i Pujol Hospital
name: Jorge Loscos Arenas, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02006290: Efficacy, Safety And Tolerability Study In Subjects With Parkinson's Disease
Official title: A Phase 1b, Randomized, Subject And Investigator-Blinded, Sponsor-Open, Placebo Controlled, Cross-Over Efficacy, Safety And Tolerability Study Of Single Oral Split Dose Administration Of PF-06412562 In Subjects With Parkinson's Disease
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Parkinson's Disease
Lead sponsor: Pfizer
Sponsor class: INDUSTRY
First posted: 2013-12-10
Enrollment: 19
Sex: ALL
Minimum age (years): 30
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: BASIC_SCIENCE

Brief summary: The B7441003 study will assess PF-06412562 for motor benefit in Parkinson's disease subjects. Safety, tolerability and PK of PF-06412562 in Parkinson's disease subjects will also be evaluated.


Eligibility criteria: Inclusion Criteria:

* Male or female subjects with a diagnosis of idiopathic Parkinson's disease.
* Daily L-dopa dose between 300 and 1200 mg.
* MBRS score \>1.

Exclusion Criteria:

* Surgical intervention for Parkinson's disease.
* History of troublesome dyskinesias.
* Any significant AXIS I psychiatric disease.

Primary outcomes:
measure: Finger tapping speed
timeFrame: 12 hours
Secondary outcomes:
measure: Maximum Observed Plasma Concentration (Cmax)
timeFrame: 0, 0.5, 1, 2, 4, 5,8,12, 24 hours
measure: Time to Reach Maximum Observed Plasma Concentration (Tmax)
timeFrame: 0, 0.5, 1, 2, 4, 0, 0.5, 1, 2, 4, 8, 12, 24 hours
measure: Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast)
timeFrame: 0, 0.5, 1, 2, 4, 0, 0.5, 1, 2, 4, 8, 12, 24 hours
measure: Apparent Oral Clearance (CL/F)
timeFrame: 0, 0.5, 1, 2, 4, 0, 0.5, 1, 2, 4, 8, 12, 24 hours
measure: Apparent Volume of Distribution (Vz/F)
timeFrame: 0, 0.5, 1, 2, 4, 8, 12, 24 hours
measure: Plasma Decay Half-Life (t1/2)
timeFrame: 0, 0.5, 1, 2, 4, 8, 12, 24 hours
measure: Mean Residence Time (MRT)
timeFrame: 0, 0.5, 1, 2, 4, 8, 12, 24 hours
measure: Number of Participants with categorical scores on the Columbia Suicide Severity Rating Scale (C-SSRS)
timeFrame: 24 hours
Other outcomes:
Locations:
city: Aventura
country: United States
facility: Pfizer Investigational Site
state: Florida
city: Baco Raton
country: United States
facility: Pfizer Investigational Site
state: Florida
city: South Miami
country: United States
facility: Pfizer Investigational Site
state: Florida
city: Bingham Farms
country: United States
facility: Pfizer Investigational Site
state: Michigan
city: Raleigh
country: United States
facility: Pfizer Investigational Site
state: North Carolina
Study officials:
affiliation: Pfizer
name: Pfizer CT.gov Call Center
role: STUDY_DIRECTOR
References:
Clinical trial NCT02532790: The Research of Standard Diagnosis and Treatment for HSPN With Mild Proteinuria in Children
Official title: The Research of Standard Diagnosis and Treatment for Henoch-Schonlein Purpura Nephritis With Mild Proteinuria in Children
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE2
Conditions: Henoch-Schoenlein Purpura Nephritis
Keywords: Mild proteinuria
Lead sponsor: Nanjing Children's Hospital
Sponsor class: OTHER
First posted: 2015-08-26
Enrollment: 100
Sex: ALL
Minimum age (years): 2
Maximum age (years): 16
Standard ages: CHILD
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This study is performed to evaluate the efficacy and safety of various measures in the treatment of HSPN with mild proteinuria in children.

Detailed description: Henoch-Schonlein purpura nephritis (HSPN) is one of the most common complications of Henoch-Schonlein purpura, and has become one of the main causes of chronic kidney disease in children. However, the diagnosis and treatment of HSPN is still based on the clinical experience, lacking of evidence-based support. This study is performed to explore the biological markers for early prediction of the prognosis and evaluate the efficacy and safety of various measures in the treatment of HSPN in children.

The patients who are proved to get HSPN by renal biopsy will be randomized to receive either prednisone p.o. or angiotensin-converting enzyme inhibitor(ACEI) p.o. We will follow up them for about 2.5 years and compare the efficacy and safety of both measures by monitoring several indexes.

Eligibility criteria: Inclusion Criteria:

* Renal biopsy proved HSPN (ISKDC class II)
* Proteinuria \< 25 mg/kg/d

Exclusion Criteria:

* The children with congenital diseases
* Proteinuria≥25 mg/kg/d

Primary outcomes:
measure: Disappearance of proteinuria
timeFrame: 30 months
Secondary outcomes:
measure: Disappearance of hematuria
timeFrame: 30 months
measure: Renal function
timeFrame: 30 months
Other outcomes:
Locations:
city: Nanjing
country: China
facility: Nanjing Children's Hospital
state: Jiangsu
Study officials:
affiliation: Department of Nephrology, Nanjing children's hospital
name: Aihua Zhang, M.D.
role: STUDY_CHAIR
References:
Clinical trial NCT02622490: Acute Effects of Different Macronutrient Compositions and Meal Distributions of the Food
Official title: Diet-induced Thermogenesis 2
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Metabolic Rate
Plasma Glucose
Serum Insulin
Serum Triglycerides
Sense of Satiety
Lead sponsor: University Hospital, Linkoeping
Sponsor class: OTHER
First posted: 2015-12-04
Enrollment: 28
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: BASIC_SCIENCE

Brief summary: About thirty participants, of varying degrees of obesity or being non-obese, without serious concomitant diseases consume either a high- or a low- carbohydrate beverage. The beverage is also consumed either as one single drink or as 5 small portions in the morning and are tested for effects on major cardiovascular risk markers and on metabolic rate for three hours on each occasion.

Detailed description: Thirty participants come to the metabolic ward at about 8 o´clock in the fasting state and stay until lunch on four occasions each. The participants are randomized to the order of the test meals. The meals have a total caloric content of 750 kcal and have either 50% of energy from carbohydrates (low fat) or 20% of energy from carbohydrates (low carb.). The meals are consumed on one occasion in the morning or divided in 5 portions (150 kcal each) for every 30 minutes, i.e. total combinations of meal composition and of meal distribution is 4. Effects of the food on p-glucose, s-insulin, blood-lipids, hormones and on metabolic rate is measured by blood tests or by indirect calorimetry (for metabolic rate). Sense of satiety is measured by visual analogue scales.

Eligibility criteria: Inclusion Criteria:

* Healthy participants \> 18 years with or without obesity

Exclusion Criteria:

* Major illnesses,
* thyroid diseases,
* need to take prednisolone,
* psychiatric disease,
* inability to understand Swedish

Primary outcomes:
measure: Metabolic rate
timeFrame: During about 3 hours
Secondary outcomes:
measure: Effects on glucose and insulin
timeFrame: 3 hours
Other outcomes:
Locations:
city: Linkoping
country: Sweden
facility: University Hospital of Linkoping
Study officials:
affiliation: Faculty of Medicine and Health Science, Linköping University, Sweden
name: Fredrik H Nystrom, MD professor
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00876590: Glucose Monitor Accuracy Investigation (Ⅱ)
Official title: Glucose Monitor Accuracy Investigation (Ⅱ)
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Healthy
Lead sponsor: National Taiwan University Hospital
Sponsor class: OTHER
First posted: 2009-04-07
Enrollment: 319
Sex: ALL
Minimum age (years): 15
Maximum age (years): 70
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: CASE_ONLY
Time perspective: CROSS_SECTIONAL
Sampling method: NON_PROBABILITY_SAMPLE
Study population: The glucose concentrations of volunteer shall be distributed as specified in ISO15197 Table 3

Brief summary: According to Section 7.3 and Section 7.4, ISO 15197(2003), it adopts the whole blood of fingertips as samples to evaluate the accuracy of portable BGM.

Detailed description: The clinical medical technologists collected blood samples from 319 volunteers including 90 diabetics and 229 healthy people. The range of the blood glucose concentration was from 30.2mg/dL to 577.5mg/dL. The result of clinic evaluation shows that the accuracy of BGM matches the requirement of ISO15197(2003).

Eligibility criteria: Inclusion Criteria:

* volunteers with diabetes and non-diabets

Exclusion Criteria:

* hypertension,fever,AIDS,hemophilia

Primary outcomes:
measure: glucose
timeFrame: 10 min
Secondary outcomes:
Other outcomes:
Locations:
city: Taipei
country: Taiwan
facility: National Taiwan University Hospital
Study officials:
affiliation: Biomedical Engineering Department of National Taiwan University Hospital
name: Feng-Huei Lin, PhD
role: STUDY_DIRECTOR
References:
Clinical trial NCT06957990: Evaluation of Music Therapy for Pre-op/Intra-op During Hernia Surgery to Decrease the Need for Narcotics
Official title: Evaluation of Music Therapy for Pre-op/Intra-op During Hernia Surgery to Decrease the Need for Narcotics
Study type: INTERVENTIONAL
Overall status: ENROLLING_BY_INVITATION
Phase: NA
Conditions: Surgery
Pain, Postoperative
Lead sponsor: TriHealth Inc.
Sponsor class: OTHER
First posted: 2025-05-06
Enrollment: 308
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: The purpose of this study is to investigate if audible distraction, in the form of music, before and/or during hernia repair surgery will decrease pain post-operatively.

Detailed description: After performing a thorough review of the literature, no studies were found that examined whether having a patient listen to a genre of music of their choosing before or during surgery impacts their postoperative pain. Music is a way to relax patients and could potentially decrease pain, which is a goal of perioperative services. The current study seeks to fill the gap and examine the impact of music on pain for surgical patients undergoing a hernia repair.

This study will use a randomized, double-blinded, controlled design with four arms:

* Arm 1: Patient will listen to music before their surgery in pre-operative area only
* Arm 2: Patient will listen to music before and during their surgery
* Arm 3: Patient will listen to music during their surgery only
* Arm 4: Patient will not listen to music during their visit

Eligibility criteria: Inclusion Criteria:

* Aged 18 years or older
* Receiving surgery at Bethesda Surgery Center

Exclusion Criteria:

* Does not speak English
* Unable to consent to involvement in the research study
* Having more than 1 hernia repair performed
* Pregnant
* Deaf
* Wears hearing aids
* Currently on medication-assisted treatment for substance use disorder (ex: suboxone or methadone)

Primary outcomes:
measure: Highest pain score reported
timeFrame: from admission to discharge from PACU, up to 8 hours
measure: Total narcotic administered
timeFrame: from admission to discharge from PACU, up to 8 hours
Secondary outcomes:
Other outcomes:
Locations:
city: Cincinnati
country: United States
facility: Bethesda Surgery Center
state: Ohio
Study officials:
References:
Clinical trial NCT03921190: Should Maxillary Buccal Infiltration Anesthesia be Given in a Closed Mouth Technique?
Official title: Should Maxillary Buccal Infiltration Anesthesia be Given in a Closed Mouth Technique? - a Clinical Study
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Anesthesia, Local
Pain Control
Keywords: Buccal infiltration anesthesia
Discomfort
Lead sponsor: University of Jordan
Sponsor class: OTHER
First posted: 2019-04-19
Enrollment: 120
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: Providing dental local anesthesia (maxillary buccal infiltration) using two techniques; open-mouth and closed-mouth
Primary purpose: OTHER

Brief summary: To study the patients' and dentists' perception of receiving/ administering maxillary buccal infiltration anesthesia using an open or closed mouth techniques

Detailed description: Background: Local anesthesia is an essential part of dentistry. The most commonly used technique to anesthetise maxillary posterior teeth is buccal infiltration with a local anesthetic agent. The technique described in the literature focuses on the location of injection, the direction of the needle insertion in relation to the root apex, the direction of needle bevel in relation to the cortical bone plate, the size of needle and the type and amount of the local anesthetic agent used. However, there is no mention to whether the patient should open their mouth or maintain their teeth in intercuspation during the injection procedure.

Aims: This research aims to a) compare two techniques of injection (open and closed-mouth techniques) in terms of the discomfort experienced by patients during the injection procedure and b) evaluate the dentists' preference in performing either of the two techniques.

Eligibility criteria: Inclusion Criteria:

* Adult patients (16 years old and older)
* Healthy (American Society of Anaesthesiologists (ASA) category I or II)
* A maxillary posterior tooth (excluding third molars) referred for root canal treatment and diagnosed with irreversible pulpitis and normal apical tissues

Exclusion Criteria:

* Psychological disorders
* Intraoral soft tissue abnormalities
* necrotic pulp with/ without apical pathology
* tenderness to palpation and/or percussion
* The use of analgesics in the preceding 12 hours before the appointment.

Primary outcomes:
measure: Patient Pain Perception
timeFrame: 5 minutes after receiving the injection
Secondary outcomes:
measure: Dentist Perception of Visibility During Anesthesia Injection
timeFrame: 30-60 days
measure: Dentist Preference of Performing One of the Two Techniques of Maxillary Buccal Infiltration; Open-mouth or Closed-mouth
timeFrame: 3-60 days
Other outcomes:
Locations:
city: Amman
country: Jordan
facility: Jordan University Hospital
state: Select One
Study officials:
affiliation: University of Jordan
name: Ahmad El-Ma'aita, PhD
role: PRINCIPAL_INVESTIGATOR
References: